HeartBeam, Inc. (NASDAQ: BEAT) disclosed that director Richard Ferrari purchased 62,500 shares of the company's common stock at $0.80 per share on April 16, 2026, a transaction valued at $50,000. The purchase was reported on a Form 4 filed with the Securities and Exchange Commission and was made in connection with the company’s underwritten public offering. Following this purchase, Ferrari's direct ownership totals 291,636 shares.
The trade took place as HeartBeam’s shares were trading at approximately $0.81, a level noted in the filing as near the company's 52-week low of $0.54. The stock had experienced a sharp 30% decline over the week preceding the transaction.
Separately, HeartBeam completed an underwritten public offering totaling 12.5 million common shares, priced at $0.80 each, generating $10 million in gross proceeds for the company. The offering agreement includes a 30-day option allowing the underwriters to purchase an additional 1.875 million shares to cover over-allotments. Company disclosures state that the proceeds are intended to support the rollout of its product, with ClearCardio identified as HeartBeam’s first commercial customer and playing a meaningful role in the planned commercialization.
Institutional interest and analyst attention have been noted in recent disclosures. B. Riley initiated coverage of HeartBeam with a Buy rating and a $4.00 price target, while D. Boral Capital also began coverage with a Buy rating and a $5.00 price target. Both firms highlighted the company’s FDA-cleared, cable-free device that can synthesize a clinical-grade 12-lead ECG as a key feature in their assessments.
In addition to the filings and analyst notes, a platform analysis cited in company disclosures characterizes the stock as undervalued and points to further detail available through a comprehensive Pro Research Report. The filing materials and announcements make clear that the recent insider purchase was executed within the framework of the public offering and that the financing is intended to advance product commercialization activities.
The combination of insider buying, a completed financing at the same price point as the director’s purchase, and the initiation of analyst coverage provides the primary factual context disclosed in filings and company statements. No additional guidance or forward-looking projections were provided in the filings beyond the stated intent for the offering proceeds.
Clear summary
Director Richard Ferrari bought 62,500 HeartBeam shares at $0.80 per share on April 16, 2026, increasing his stake to 291,636 shares. The purchase was associated with the company's underwritten public offering, which raised $10 million from the sale of 12.5 million shares at $0.80 apiece and included a 30-day overallotment option for 1.875 million additional shares. The stock was trading near $0.81, close to a 52-week low, after a recent 30% decline. B. Riley and D. Boral Capital each initiated coverage with Buy ratings and respective price targets of $4.00 and $5.00.
Key points
- Insider transaction - Director Richard Ferrari purchased 62,500 shares at $0.80, bringing his holdings to 291,636 shares; transaction filed on Form 4 with the SEC.
- Financing completed - HeartBeam closed a 12.5 million share offering at $0.80 per share, raising $10 million in gross proceeds, with a 30-day option for 1.875 million additional shares.
- Analyst attention - B. Riley and D. Boral Capital initiated coverage with Buy ratings and price targets of $4.00 and $5.00; company highlights an FDA-cleared, cable-free device capable of synthesizing a clinical-grade 12-lead ECG.
Risks and uncertainties
- Share price volatility - The stock recently fell 30% in a single week and traded close to its 52-week low, indicating market sensitivity in the healthcare equipment and small-cap equities sectors.
- Financing dependence - The company’s stated use of proceeds to support product rollout suggests reliance on the offering proceeds to advance commercialization, which affects operational and capital markets risk.
- Coverage and expectations - New analyst coverage brings attention but also creates expectation risk if commercial milestones tied to the product rollout or the role of ClearCardio as a customer do not proceed as outlined in company statements.